Citation Impact
Citing Papers
Demystifying theory and its use in improvement
2015
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
2005 Standout
Sex Differences in the Gut Microbiome Drive Hormone-Dependent Regulation of Autoimmunity
2013 StandoutScience
Development and validation of the Nancy histological index for UC
2015 Standout
Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework
2017 Standout
The development of Cop 1 (Copaxone®), and innovative drug for the treatment of multiple sclerosis: personal reflections
1996
Inflammation and Alzheimer's disease
2000 Standout
Neuroinflammation in Parkinson's disease: a target for neuroprotection?
2009 Standout
Treatment of multiple sclerosis with Copolymer-1 (Copaxone®): implicating mechanisms of Th1 to Th2/Th3 immune-deviation
1998
The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease
2006
Glatiramer acetate for the treatment of multiple sclerosis
2004
The Blood–Brain Barrier
2015 Standout
Sjögren's syndrome
2005 Standout
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial
2007
Regulatory T cells exert checks and balances on self tolerance and autoimmunity
2009 StandoutNobel
The mental health of civilians displaced by armed conflict: an ecological model of refugee distress
2016
Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
1997
Therapeutic apheresis in neurological disorders
2000
Circulating natural killer cells but not cytotoxic T lymphocytes are reduced in patients with active relapsing multiple sclerosis and little clinical disability as compared to controls
1995
MHC class II proteins and disease: a structural perspective
2006
Health Tracking for Improved Humanitarian Performance
2007
Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007–2012
2014 Standout
Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease
2014 Standout
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
2008 Standout
Multiple sclerosis
2008 Standout
Lack of evidence for use of glatiramer acetate in multiple sclerosis
2004
Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis
2017
Copolymer 1: from basic research to clinical application
1997
The origin and application of experimental autoimmune encephalomyelitis
2007
Immunopathology of multiple sclerosis
2015 Standout
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
2021 Standout
A Brief History of the Use of Interferons as Treatment of Multiple Sclerosis
1994
The T Lymphocyte in Experimental Allergic Encephalomyelitis
1990
Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
2012 Standout
What is meant by intention to treat analysis? Survey of published randomised controlled trials
1999 Standout
The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy
2004 Standout
Ulcerative colitis
2016 Standout
Once-Daily Budesonide MMX® Extended-Release Tablets Induce Remission in Patients With Mild to Moderate Ulcerative Colitis: Results From the CORE I Study
2012
Antibody Association with a Novel Model for Primary Progressive Multiple Sclerosis: Induction of Relapsing‐Remitting and Progressive Forms of EAE in H2S Mouse Strains
2000
The role of regulatory T cells in controlling immunologic self-tolerance
2003 StandoutNobel
Multiple Sclerosis
2000 Standout
New Multiple Sclerosis Phenotypic Classification
2014 Standout
Ulcerative colitis
2020 Standout
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
2008
Histologic Evaluation of Ulcerative Colitis
2014
Natural history of multiple sclerosis
1994
Treatment of multiple sclerosis
1994
Trauma-focused therapy for refugees: Meta-analytic findings.
2014
Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses
1996
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
2004 Standout
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
2005 Standout
The dawning era of polymer therapeutics
2003 Standout
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis
2018
Multiple sclerosis
2002 Standout
The Human Cancer Antigen Mesothelin Is More Efficiently Presented to the Mouse Immune System when Targeted to the DEC‐205/CD205 Receptor on Dendritic Cells
2009 StandoutNobel
Recent developments in the treatment of inflammatory bowel disease
2013
Recent progress in the diagnosis and treatment of multiple sclerosis
1999
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
2013
Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis
1994 StandoutScience
Mechanisms of action of glatiramer acetate in multiple sclerosis
2001
Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
2015
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
1998 Standout
The Natural History of Multiple Sclerosis
1995
SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process
2015 Standout
Revised diagnostic criteria for neuromyelitis optica
2006 Standout
Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
2000
Mapping spatial patterns of urban agriculture in Rome (Italy) using Google Earth and web-mapping services
2016
The outbreak of COVID-19 coronavirus and its impact on global mental health
2020 Standout
Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis
2018
Multiple Sclerosis
2018 Standout
Immunotherapy for multiple sclerosis.
1994
Blood—Brain Barrier Genomics
2001
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
IMMUNOLOGY OF MULTIPLE SCLEROSIS
2005 Standout
The Social Determinants of Refugee Mental Health in the Post-Migration Context: A Critical Review
2017 Standout
Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis
1993 Science
Minocycline: far beyond an antibiotic
2013 Standout
How Parents' Negative Experiences at Immunization Visits Affect Child Immunization Status in a Community in New York City
2011
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Glatiramer acetate in combination with minocycline in patients with relapsing—remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial
2009
The clinical course of neuromyelitis optica (Devic’s syndrome)
1999 Standout
Behavioural responses of wildlife to urban environments
2012 Standout
Review article: integrating budesonide‐MMX into treatment algorithms for mild‐to‐moderate ulcerative colitis
2014
Assessing Atropisomer Axial Chirality in Drug Discovery and Development
2011 Standout
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
2001
Noise-dependent song amplitude regulation in a territorial songbird
2002
The Role of Urban Agriculture as a Nature-Based Solution: A Review for Developing a Systemic Assessment Framework
2018 Standout
Humanitarian accountability and performance in the Théâtre de l’Absurde
2010 Standout
Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing–remitting MS
2007
Psychological therapies for the treatment of mental disorders in low- and middle-income countries affected by humanitarian crises
2018
The contemporary refugee crisis: an overview of mental health challenges
2017
Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]
2002
Works of William Weiss being referenced
Community-based mental health treatments for survivors of torture and militant attacks in Southern Iraq: a randomized control trial
2015
A Common Elements Treatment Approach for Adult Mental Health Problems in Low- and Middle-Income Countries
2013
Factors Associated with Missed Vaccination during Mass Immunization Campaigns
2009
Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9mg extended-release tablets in patients with active left-sided ulcerative colitis
2009
Expanding the Scope of Humanitarian Program Evaluation
2007
Using a logic model to design and evaluate quality and patient safety improvement programs
2012
A two-stage cluster sampling method using gridded population data, a GIS, and Google EarthTM imagery in a population-based mortality survey in Iraq
2012
A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple Sclerosis
1987
The vanished Lombard effect
1993
A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis
1991